Add BrightSurf on Google Email

The Lancet


The Lancet Neurology press release

Researchers explore the role of dopamine in the placebo effect, which shows promise for treating Parkinson's disease, depression, and pain. Meanwhile, preclinical studies on bone-marrow stromal cells suggest potential therapeutic benefits for neural injury treatments like stroke.

SourceThe Lancet_DELETED·JournalThe Lancet Neurology·DateMay 15, 2002

Study highlights need for hepatitis C vaccine

A recent study found that people previously infected with HCV are 12 times less likely to develop persistent infection than those infected for the first time. This suggests that immunity can be acquired to protect against viral persistence, making vaccines a potential solution to reduce medical consequences of HCV infection.

SourceThe Lancet_DELETED·JournalThe Lancet·DateApr 24, 2002

New treatment option for children with malaria

A new treatment combination of amodiaquine and artesunate has shown high cure rates for uncomplicated malaria in children under 11 years old. The study found that the treatment was more effective than amodiaquine alone, with higher cure rates in Gabon compared to Kenya and Senegal.

SourceThe Lancet_DELETED·JournalThe Lancet·DateApr 18, 2002

The Lancet Neurology launched

The Lancet Neurology aims to report the most important advances in neurology, predicting risk of neurological conditions through genetics and imaging. Experimental therapies like gene therapy and stem cells offer potential for treating neurological disorders.

SourceThe Lancet_DELETED·JournalThe Lancet Neurology·DateApr 15, 2002

Nicorandil could improve outcome for angina patients

A randomized trial found that nicorandil reduced the risk of cardiovascular events in patients with stable angina, including deaths due to coronary heart disease and non-fatal heart attacks. The study showed a significant reduction in acute coronary syndromes and all cardiovascular events compared to the placebo group.

SourceThe Lancet_DELETED·JournalThe Lancet·DateApr 11, 2002

Support for colorectal cancer screening

A UK trial suggests that flexible sigmoidoscopy is a suitable tool for population screening of colorectal cancer, with high attendance rates and low perforation risks compared to colonoscopy. The study's findings highlight the need for tailored approaches to screening, taking into account individual risk factors and efficiency.

SourceThe Lancet_DELETED·JournalThe Lancet·DateApr 11, 2002

Early promise for dementia drug

A new study found that galantamine improves cognition and daily living activities in patients with vascular dementia. The medication was also shown to reduce symptoms of behavioural changes, providing a potential treatment option for patients with limited pharmacological help.

SourceThe Lancet_DELETED·JournalThe Lancet·DateApr 11, 2002

Violence against women

The Lancet series highlights the prevalence of gender-based violence worldwide, which accounts for as much death and ill-health in women aged 15-44 years as cancer. The World Bank reports that violence against women is a greater cause of ill-health than malaria and traffic accidents combined.

SourceThe Lancet_DELETED·JournalThe Lancet·DateApr 4, 2002

Ace inhibitors could slow muscle decline

Researchers found that continuous ACE inhibitor users had a lower average decline in muscle strength and walking speed compared to intermittent users of other antihypertensive drugs. The study suggests that ACE inhibitors could be used to slow physical decline in elderly people without congestive heart failure.

SourceThe Lancet_DELETED·JournalThe Lancet·DateMar 14, 2002